CNAT - Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics

NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to 10 percent on $60 billion worth of U.S. in response to U.S. tariffs. The Dow Jones Industrial Average gained 0.71 percent to close at 26,246.96, while the S&P 500 Index hiked 0.54 percent to close at 2,904.31. The Nasdaq Composite Index jumped 0.76 percent to close at 7,956.11.

“In my opinion, I see President Trump as trying to force the trading partners to the bargaining table to renegotiate trade deals that have long favored other countries over the U.S. His methods are unconventional but the U.S. economy is strong, earnings are healthy and confidence among consumers and investors remains high,” said chief investment strategist at SlateStone Wealth, Robert Pavlik.

RDI Initiates Coverage on:

Conatus Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=CNAT

INSYS Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=INSY

Conatus Pharmaceuticals' stock jumped 12.98% Tuesday, to close the day at $4.70. The stock recorded a trading volume of 1,108,326 shares, which was above its three months average volume of 430,557 shares. In the last year, Conatus Pharmaceuticals' shares have traded in a range of 3.22 - 7.95. The share price has gained 45.96% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.44 is below its 200-day moving average of $4.60. Shares of Conatus Pharmaceuticals have gained roughly 18.69 percent in the past month and are up 1.73 percent year-to-date.

Access RDI's Conatus Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CNAT

On Tuesday, shares of INSYS Therapeutics recorded a trading volume of 1,283,821 shares, which was above the three months average volume of 800,803 shares. The stock ended the day 11.06% higher at $9.24. The share price has fallen 34% from its 52 week high with a 52 week trading range of 4.10 - 14.00. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.81 is above its 200-day moving average of $7.24. Shares of INSYS Therapeutics have gained roughly 19.53 percent in the past month and are down 3.95 percent year-to-date.

Access RDI's INSYS Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INSY

Our Actionable Research on Conatus Pharmaceuticals Inc. (NASDAQ : CNAT ) and INSYS Therapeutics, Inc. (NASDAQ :INSY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com